Filing Flows › Kura Oncology (KURA) › How it makes money
How Kura Oncology (KURA) makes money
Kura Oncology (KURA) made $20.9M of revenue in the second quarter 2026 (Q2 2026), +37% from a year earlier. License and Collaboration Revenue brought in $11.8M (56%); Product brought in $9.1M (44%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| License and Collaboration Revenue | $11.8M | 56.3% | -6% | -23% |
| Product | $9.1M | 43.7% | +58% | — |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $20.9M | 100.0% |
| Income tax | $5K | 0.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $20.9M | +36% |
| Q1 2026 | $18.3M | +30% |
| Q4 2025 | $17.3M | — |
| Q3 2025 | $20.8M | — |
| Q2 2025 | $15.3M | — |
| Q1 2025 | $14.1M | — |
From Kura Oncology's 10-Q filed Aug 12, 2026 (on EDGAR).
Questions
How does Kura Oncology make money?
Kura Oncology (KURA) made $20.9M of revenue in the second quarter 2026 (Q2 2026), +37% from a year earlier. License and Collaboration Revenue brought in $11.8M (56%); Product brought in $9.1M (44%).
What is Kura Oncology's biggest business?
License and Collaboration Revenue: $11.8M in the second quarter 2026, 56% of revenue, -23% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.